Clinical benefit of ertapenem compared to flomoxef for the treatment of cefotaxime-resistant Enterobacteriaceae bacteremia
Infection and Drug Resistance Mar 17, 2018
Lee C, et al. - In a retrospective study on adults with bloodstream infection (BSI) caused by flomoxef-susceptible cefotaxime-resistant Enterobacteriaceae (CE), researchers investigated the efficacy of flomoxef compared with that of ertapenem. Findings revealed similar outcomes with the two regimens. However, ertapenem therapy was observed to be associated with a shorter hospitalization time in adults after CE BSI.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries